Dapoxetine
- Generic Name
- Dapoxetine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23NO
- CAS Number
- 119356-77-3
- Unique Ingredient Identifier
- GB2433A4M3
- Background
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in De...
- Indication
For the treatment of premature ejaculation.
- Associated Conditions
- Premature Ejaculation
- Associated Therapies
- -
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 199
- Registration Number
- NCT00210613
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 1294
- Registration Number
- NCT00211107
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 1320
- Registration Number
- NCT00211094
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath